dc.contributor.author | Yarali, H | |
dc.contributor.author | Yildiz, BO | |
dc.contributor.author | Demirol, A | |
dc.contributor.author | Zeyneloglu, HB | |
dc.contributor.author | Yigit, N | |
dc.contributor.author | Bukulmez, O | |
dc.contributor.author | Koray, Z | |
dc.date.accessioned | 2019-12-12T06:40:13Z | |
dc.date.available | 2019-12-12T06:40:13Z | |
dc.date.issued | 2002 | |
dc.identifier.issn | 0268-1161 | |
dc.identifier.uri | https://doi.org/10.1093/humrep/17.2.289 | |
dc.identifier.uri | http://hdl.handle.net/11655/16509 | |
dc.description.abstract | BACKGROUND: This study aims to evaluate the impact of metformin on ovarian response when co-administered during recombinant (r)FSH using the low-dose step-up protocol in clomiphene citrate-resistant polycystic ovarian syndrome (PCOS) patients with normal glucose tolerance. METHODS AND RESULTS: Thirty-two patients were randomized to metformin (n = 16) and placebo (n = 16) groups. Hormonal assessment, a 75 g oral glucose tolerance test (OGTT) and a frequently sampled i.v. glucose tolerance test (FSIGTT) were performed before and after oral administration of metformin (850 mg twice daily) or placebo for 6 weeks. Recombinant FSH treatment was undertaken, thereafter, in women who did not ovulate on metformin (n = 10) or placebo (n = 15). There was no significant change in all insulin sensitivity indices in both groups. The only change noted was a decline in mean serum free testosterone concentration in the metformin group (P = 0.049). One patient on placebo and six patients on metformin ovulated spontaneously (P < 0.05). All parameters of ovarian response were comparable between the two groups during rFSH treatment. Combining the 6 week placebo or metformin-only period with a single rFSH treatment cycle, the overall ovulation rates were 75 and 94% in the placebo and metformin groups respectively (P > 0.05). The respective figures for pregnancy were 6.3 and 31.3% (P > 0.05). CONCLUSIONS: Metformin may restore ovulation with no improvement on insulin resistance in clomiphene citrate-resistant PCOS patients with normal glucose tolerance, but has no significant effect on ovarian response during rFSH treatment. | |
dc.language.iso | en | |
dc.publisher | Oxford Univ Press | |
dc.relation.isversionof | 10.1093/humrep/17.2.289 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Obstetrics & Gynecology | |
dc.subject | Reproductive Biology | |
dc.title | Co-Administration Of Metformin During Rfsh Treatment In Patients With Clomiphene Citrate-Resistant Polycystic Ovarian Syndrome: A Prospective Randomized Trial | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Human Reproduction | |
dc.contributor.department | Kadın Hastalıkları ve Doğum | |
dc.identifier.volume | 17 | |
dc.identifier.issue | 2 | |
dc.identifier.startpage | 289 | |
dc.identifier.endpage | 294 | |
dc.description.index | WoS | |